Scancell, the developer of novel immunotherapies for the treatment of cancer, announces that further to the recent update of results from its on-going Phase 1/2 clinical trial on 2 June 2014, options over 500,000 ordinary shares (the “Options”) have been granted on 18 June 2014 to Dr Sally Adams, who was appointed as the Company’s Development Director on 1 May 2014.

The options, which were granted under an EMI Approved Share Option Scheme, vest over a period of three years, and are subject to the achievement of performance criteria including scientific and commercial milestones as specified by the Remuneration Committee. The exercise price of the options is 30.5p, the closing price of Scancell shares on 17 June 2014.

For Further Information:

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.